Management of candidemia and invasive candidiasis

被引：5

作者：

Taieb, F. ^{[1
,2
]}

Mechai, F. ^{[1
,2
]}

Lefort, A. ^{[3
]}

Lanternier, F. ^{[1
,2
]}

Bougnoux, M. -E. ^{[6
]}

Lortholary, O. ^{[1
,2
,4
,5
]}

机构：

[1] Ctr Infectiol Necker Pasteur, Paris, France

[2] Univ Paris 05, Hop Necker Enfants Malad, Serv Malad Infect & Trop, Ctr Infectiol Necker Pasteur, F-75743 Paris 15, France

[3] Univ Paris Diderot, Hop Beaujon, Serv Med Interne, F-92110 Clichy, France

[4] Ctr Natl Reference Mycol & Antifong, Inst Pasteur, F-75015 Paris, France

[5] CNRS, URA 3012, Paris, France

[6] Univ Paris 05, Hop Necker Enfants Malad, Serv Mycol & Parasitol, F-75015 Paris, France

来源：

REVUE DE MEDECINE INTERNE | 2011年 / 32卷 / 03期

关键词：

Candida spp; Invasive infection; Treatment; BLOOD-STREAM INFECTIONS; INTENSIVE-CARE-UNIT; HOSPITAL-ACQUIRED CANDIDEMIA; IN-VITRO SUSCEPTIBILITIES; LIPOSOMAL AMPHOTERICIN-B; RISK-FACTORS; FUNGAL-INFECTIONS; RANDOMIZED-TRIAL; CANCER-PATIENTS; EPIDEMIOLOGY;

D O I：

10.1016/j.revmed.2010.08.019

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Candida species is the fourth most common cause of bloodstream infection and is the leading cause of invasive fungal infection among hospitalized patients. Acute disseminated candidiasis remains a life-threatening disease that now occurs mainly in intensive care units hospitalized patients. Delay in treatment of Candida bloodstream infections could be minimized by the development of more rapid and sensitive diagnostic techniques for the identification of Candida bloodstream infections. Current guidelines for the management of invasive candidiasis recommend fluconazole or an echinocandin as the primary therapeutic option. The optimal choice of the antifungal agent should depend on local epidemiology, prior antifungal therapy and patient's characteristics. (c) 2010 Societe nationale francaise de medecine interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.

引用

页码：173 / 180

页数：8

共 53 条

[11] British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections [J].

Denning, DW ;

Kibbler, CC ;

Barnes, RA .

LANCET INFECTIOUS DISEASES, 2003, 3 (04) :230-240

[12] Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study [J].

Diekema, DJ ;

Messer, SA ;

Brueggemann, AB ;

Coffman, SL ;

Doern, GV ;

Herwaldt, LA ;

Pfaller, MA .

JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (04) :1298-1302

[13] International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections [J].

Edwards, JE ;

Bodey, GP ;

Bowden, RA ;

Buchner, T ;

dePauw, BE ;

Filler, SG ;

Ghannoum, MA ;

Glauser, M ;

Herbrecht, R ;

Kauffman, CA ;

Kohno, S ;

Martino, P ;

Meunier, F ;

Mori, T ;

Pfaller, MA ;

Rex, JH ;

Rogers, TR ;

Rubin, RH ;

Solomkin, J ;

Viscoli, C ;

Walsh, TJ ;

White, M .

CLINICAL INFECTIOUS DISEASES, 1997, 25 (01) :43-59

[14] Utility of Galactomannan Enzyme Immunoassay and (1,3) β-D-Glucan in Diagnosis of Invasive Fungal Infections: Low Sensitivity for Aspergillus fumigatus Infection in Hematologic Malignancy Patients [J].

Hachem, R. Y. ;

Kontoyiannis, D. P. ;

Chemaly, R. F. ;

Jiang, Y. ;

Reitzel, R. ;

Raad, I. .

JOURNAL OF CLINICAL MICROBIOLOGY, 2009, 47 (01) :129-133

[15] Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program [J].

Hajjeh, RA ;

Sofair, AN ;

Harrison, LH ;

Lyon, GM ;

Arthington-Skaggs, BA ;

Mirza, SA ;

Phelan, M ;

Morgan, J ;

Lee-Yang, W ;

Ciblak, MA ;

Benjamin, LE ;

Sanza, LT ;

Huie, S ;

Yeo, SF ;

Brandt, ME ;

Warnock, DW .

JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (04) :1519-1527

[16] Voriconazole: A new triazole antifungal agent [J].

Johnson, LB ;

Kauffman, CA .

CLINICAL INFECTIOUS DISEASES, 2003, 36 (05) :630-637

[17] RISK-FACTORS FOR CANDIDEMIA IN CANCER-PATIENTS - A CASE-CONTROL STUDY [J].

KARABINIS, A ;

HILL, C ;

LECLERCQ, B ;

TANCREDE, C ;

BAUME, D ;

ANDREMONT, A .

JOURNAL OF CLINICAL MICROBIOLOGY, 1988, 26 (03) :429-432

[18] Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial [J].

Kullberg, BJ ;

Sobel, JD ;

Ruhnke, M ;

Pappas, PG ;

Viscoli, C ;

Rex, JH ;

Cleary, JD ;

Rubinstein, E ;

Church, LWP ;

Brown, JM ;

Schlamm, HT ;

Oborska, IT ;

Hilton, F ;

Hodges, MR .

LANCET, 2005, 366 (9495) :1435-1442

[19] Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial [J].

Kuse, Ernst-Ruediger ;

Chetchotisakd, Ploenchan ;

da Cunha, Clovis Arns ;

Ruhnke, Markus ;

Barrios, Carlos ;

Raghunadharao, Digumarti ;

Sekhon, Jagdev Singh ;

Freire, Antonio ;

Ramasubramanian, Venkatasubramanian ;

Demeyer, Ignace ;

Nucci, Marcio ;

Leelarasamee, Amorn ;

Jacobs, Frederique ;

Decruyenaere, Johan ;

Pittet, Didier ;

Ullmann, Andrew J. ;

Ostrosky-Zeichner, Luis ;

Lortholary, Olivier ;

Koblinger, Sonja ;

Diekmann-Berndt, Heike ;

Cornely, Oliver A. .

LANCET, 2007, 369 (9572) :1519-1527

[20] Liposomal amphotericin B: what is its role in 2008? [J].

Lanternier, F. ;

Lortholary, O. .

CLINICAL MICROBIOLOGY AND INFECTION, 2008, 14 :71-83

← 1 2 3 4 5 6 →